Abstract
N6-methyladenosine (m(6)A) is the product of the most prevalent mRNA modification in eukaryotic cells. Accumulating evidence shows that tumor microenvironment (TME) plays a pivotal role in tumor development. However, the underlying relationship between m(6)A modification and the TME of a papillary renal cell carcinoma (PRCC) is still unclear. To investigate the relationship between m(6)A modification and prognosis and immunotherapeutic efficacy for PRCC, we looked for distinct m(6)A modification patterns based on 23 m(6)A-related genes. Next, the correlation between m(6)A modification patterns and TME-related characteristics was investigated. Then, the intersected differentially expressed genes were selected and the scoring system, denoted as m(6)A score, was established to evaluate m(6)A modification, prognosis, and immunotherapeutic efficacy. In this study, three distinct m(6)A expression clusters were identified. Based on the results of immune cell infiltration analysis and functional analysis, carcinogenic pathways, TME-related immune cells, and pathways were identified as well. More importantly, the established m(6)A score showed good value in predicting clinical outcomes according to results using external cohorts. Specifically, PRCC patients with low m(6)A score value showed better survival, immunotherapeutic response, and higher tumor mutation burden. Furthermore, immunohistochemistry using PRCC clinical samples from our medical center was carried out and verified our results. In conclusion, this study highlights the underlying correlation between m(6)A modification and the immune landscape and, hence, enhances our understanding of the TME and improved the therapeutic outlook for PRCC patients.